Apr 06, 2023
Human neuroblastoma cell line SH-SY5Y culturing
- Qing Wang1,2
- 1Massachusetts General Hospital;
- 2Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network
Protocol Citation: Qing Wang 2023. Human neuroblastoma cell line SH-SY5Y culturing. protocols.io https://dx.doi.org/10.17504/protocols.io.ewov1ow42lr2/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: April 06, 2023
Last Modified: May 31, 2024
Protocol Integer ID: 80145
Keywords: ASAPCRN
Funders Acknowledgement:
From cancer associations to altered immunity in the pathogenesis of Parkinson's disease
Grant ID: ASAP-000312
Abstract
This is the brief protocol for seeding and culturing human neuroblastoma SH-SY5Y cells.
1. SH-SY5Y cells (ATCC, Manassas, VA, USA, Cat# CRL-2266, RRID:CVCL_0019) were seeded at 70-80% density.
2. Change medium to DMEM/F12 supplemented with 15% FBS, 1% penicillin-streptomycin and 10μM retinoic acid (11320-033, Gibco) for differentiation for four days
Protocol references
Xicoy, H., Wieringa, B., & Martens, G. J. (2017). The SH-SY5Y cell line in Parkinson’s disease research: a systematic review.Molecular neurodegeneration,12, 1-11.
Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Cena, V., ... & Comella, J. X. (2000). Sequential treatment of SH‐SY5Y cells with retinoic acid and brain‐derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor‐dependent, human neuron‐like cells.Journal of neurochemistry,75(3), 991-1003.